Quebec Low Back Pain Core Study (QLBP Core) and Quebec Low Back Pain Biobank (QLBP Biobank)
Low back pain (LBP) is reported by approximately 20% of North Americans, the majority of whom experience both pain and physical impairment. Patients with chronic LBP have an increased utilization of medical services, and higher incidence of lost workdays and long-term disability, representing a significant burden to the healthcare system and the economy.
To better understand why some people recover from and/or respond to some treatments while other do not, we have established a province-wide online database for longitudinal studies of individuals with acute and chronic LBP (Core). The Core Database is not only a valuable research tool by itself but can also facilitate recruitment for a series of affiliated projects, including the QLBP Biobank, where biological samples are collected. The collection of biological samples (i.e. blood samples and saliva) from people suffering with LBP will allow the investigation of genetic, epigenetic, and proteomic markers that are linked to LBP diagnosis, prognosis, and treatment.
Who can participate?
If you are 18 years old or older, you have low back pain, you have internet access, and you are fluent in English or French, you are eligible to participate in the QLBP Core Study. If you live in the greater Montreal area and you are willing to donate blood you can participate in the QLBP Biobank too.
What will I have to do?
To participate in the QLBP Core Study you will have to register online and answer some online questionnaires at baseline and after 3, 6, 12, and 24 months.
To participate in the QLBP Biobank in addition to that mentioned above, you will have to go to The Alan Edwards Centre for Research on Pain (McGill University) for a visit and to donate blood and saliva samples.
How can I participate?
If you would like to participate please click here.
This study is supported by the Strategy for Patient Oriented Research (SPOR) Program – Canadian Institutes of Health Research (CIHR) grant SCA145102 to Dr. Diatchenko. This study has been reviewed and approved by the Research Ethics and Compliance (IRB) committee of the Faculty of Medicine of McGill University (protocol number: NUMBER: A08-M23-18A).